UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 6-K
------------
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
SEPTEMBER 10, 2007
------------
CRUCELL NV
(Exact name of registrant as specified in its charter)
P.O. BOX 2048 ARCHIMEDESWEG 4 2333 CN LEIDEN THE NETHERLANDS
(Address of principal executive offices)
000-30962
(Commission File Number)
------------
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F:
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether the registrant by furnishing the information
contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
CRUCELL APPOINTS MR. CEES DE JONG AS CHIEF OPERATING OFFICER
LEIDEN, THE NETHERLANDS, SEPTEMBER 10, 2007 - Dutch biotechnology company
Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced the
appointment of Mr. Cees de Jong to the position of Chief Operating Officer. Mr.
de Jong will serve as a member of Crucell's Management Committee.
"Cees de Jong is an experienced senior executive and we are excited he has
joined Crucell," said Dr. Ronald H.P. Brus, Crucell's Chief Executive Officer.
"He has strong qualifications to bring operational excellence to our worldwide
organization. His extensive management experience will make an important
contribution to Crucell's ambitious growth strategy."
Prior to joining Crucell, Mr. de Jong was Group Vice President in charge of the
Flavours Division at Quest International in the Netherlands. He was a member of
Quest International's Management Board. Mr. de Jong was responsible for turning
around the Flavours Division, leading up to the (euro)1,8 billion acquisition of
Quest International by market leader Givaudan.
Mr. de Jong remains a member of Quest International's Dutch Supervisory Board.
He is also Chairman of GreenChem BV's Supervisory Board. Prior to joining Quest,
Mr. de Jong worked as Managing Director of DSM Anti-infectives, a $625 million
global business, employing more than 4000 people worldwide. In 1989, he started
his career at Gist Brocades, holding a number of positions in business
development, strategy and general management before the company was acquired by
DSM in 1998. Mr. de Jong holds a Medical Degree as well as a MBA from Erasmus
University in Rotterdam.
ABOUT CRUCELL
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology
company focused on research, development and worldwide marketing of vaccines and
antibodies that prevent and treat infectious diseases. Its vaccines are sold in
public and private markets worldwide. Crucell's core portfolio includes a
vaccine against hepatitis B, a fully-liquid vaccine against five important
childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell
also markets travel vaccines, such as the only oral anti-typhoid vaccine, an
oral cholera vaccine and the only aluminium-free hepatitis A vaccine on the
market. The Company has a broad development pipeline, with several Crucell
products based on its unique PER.C6(R) production technology. The Company
licenses this and other technologies to the biopharmaceutical industry.
Important partners and licensees include DSM Biologics, sanofi aventis, GSK and
Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with
subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company
employs over a 1000 people. For more information, please visit www.crucell.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements that involve inherent
risks and uncertainties. We have identified certain important factors that may
cause actual results to differ materially from those contained in such
forward-looking statements. For information relating to these factors please
refer to our Form 20-F, as filed with the U.S. Securities and Exchange
Commission on June 13, 2007, and the section entitled "Risk Factors". The
Company prepares its financial statements under generally accepted accounting
principles in the United States (US GAAP) and Europe (IFRS).
FOR FURTHER INFORMATION PLEASE CONTACT:
MEDIA: INVESTORS/ANALYSTS:
Barbara Mulder Oya Yavuz
Director Corporate Communications Director Investor Relations
Tel: 31-(0) 71 519 7346 Tel. +31-(0) 71-519 7064
press@crucell.com ir@crucell.com
www.crucell.com www.crucell.com
SIGNATURES
Pursuant to the requirements of the Securities Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
CRUCELL NV
-----------------------------------------
(Registrant)
SEPTEMBER 10, 2007 /s/ LEON KRUIMER
- ------------------------ -----------------------------------------
(Date) Leon Kruimer
Chief Financial Officer